TrialReader


A Trial Using CD133 Enriched Bone Marrow Cells Following Primary Angioplasty for Acute Myocardial Infarction

NCT00529932 — Not applicable, Terminated, 19 participants, Jozef Bartunek

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Trial Using CD133 Enriched Bone Marrow Cells Following Primary Angioplasty for Acute Myocardial Infarction

RegistryNCT00529932, acronym SELECT-AMI
StatusTerminated - Insufficient recruitment
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: quadruple, treatment
Enrollment19 (Actual)
SponsorJozef Bartunek (Other); collaborators: King's College London
ConditionsAcute Myocardial Infarction
InterventionsCD133+ infusion, placebo infusion (Other)
Datesstart 2007-09-01, primary completion 2011-12-01, completion 2012-12-01, first posted 2007-09-14, last updated 2015-04-22
Locations5 sites in Belgium, France, Netherlands, United Kingdom

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Acute Myocardial Infarction All trials of CD133+ infusion All trials of placebo infusion

-Summary

An international, multi-centre, double-blind, randomised, placebo-controlled clinical trial with central core lab analyses to determine the safety of intra-coronary infusion of enriched CD133+, bone marrow-derived, autologous progenitor cells in patients 5-10 days after acute percutaneous coronary revascularization (primary PCI) for ST-segment elevation myocardial infarction (STEMI).

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
1Active comparatorOther: CD133+ infusionEnriched CD133+, bone marrow-derived, autologous progenitor cells for this trial will be infused in the coronary arteries
2Placebo comparatorOther: placebo infusionControl group patients will receive 3 injections of 0.3 mL each of buffered normal saline (the vehicle used for cell suspension) into comparable vessels. Subjects will have an identical intra-coronary injection procedure to those randomized to autologous CD133+ progenitor cell injections.
  • CD133+ infusion (Other): Subjects will be infused with all available autologous CD133+ cells after processing during one infusion session (during angiography).
  • placebo infusion (Other): Buffered normal saline will be infused in the coronary artery during an angiography.

+Outcome measures

Primary outcomes

  • PRIMARY SAFETY ENDPOINT Comparison of progression in coronary atherosclerosis burden proximal and distal to the stented segment of the infarct-related artery in treated and control groups. [at 6 months post-infusion]
  • PRIMARY EFFICACY ENDPOINT Comparison of changes in myocardial thickening in non-viable akinetic / hypokinetic LV wall segments as determined by cardiac magnetic resonance imaging (cMRI) in treated and control groups. [at 6 and 24 months]

Secondary outcomes

  • SECONDARY SAFETY ENDPOINT (a) Development of ventricular arrhythmias including failed sudden cardiac death. (b) Development of congestive heart failure. [At all follow up's]
  • SECONDARY EFFICACY ENDPOINTS (a) Changes in % global LV ejection fraction (EF) compared with baseline as determined by cMRI and echocardiography pre- and post-cell infusion subsequent to primary PCI. [at all follow up's]
  • SECONDARY EFFICACY ENDPOINTS (b)Assessment of epicardial resistance and microvascular resistance, index of myocardial resistance and absolute coronary blood flow measurements in the infarct related artery. [at 6 months follow up]
  • SECONDARY EFFICACY ENDPOINTS (c) The feasibility of the CliniMACS® Reagent System to yield 5x106 CD133+ cells from 100-150 ml of autologous bone marrow. [prior to the infusion]

+Eligibility

Sex: All, ages: 20 Years to 75 Years

Inclusion Criteria:

* Primary PCI for acute STEMI between 2-24 hours after onset of chest pain.
* ST-segment elevation >=2mm in >=3 adjacent leads.
* Presence of severe hypokinesia and/or akinesia in >=2 adjacent segments on echocardiogram at 48-72 hrs after primary PCI.
* Age between 20 and 75 years.

Exclusion Criteria:

* Pregnant or lactating.
* Prior history of myocardial infarction before index event.
* Decompensated congestive heart failure.
* Pre-existent LV dysfunction (EF <45% prior to admission)
* Cardiomyopathy.
* Previous cardiac surgery.
* Congenital heart disorder.
* Serum creatinine >200 Mmol/L.
* Presence of permanent pacemaker or implantable defibrillator.
* Contraindication to bone marrow aspiration.
* History of malignancy within 5 years except curatively treated basal cell carcinoma, squamous cell carcinoma and/or cervical carcinoma.
* Sustained or inducible VT >48 hours post primary PCI.
* Three vessel coronary artery disease necessitating intervention within 4 months.
* Immune compromise including chronic human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.
* Presence of chronic systemic inflammatory disorders.
* Previous autologous or allogeneic bone marrow or peripheral stem cell transplant or prior solid organ transplantation.
* Low hemoglobin, white blood cell, absolute neutrophil and/or platelet count.
* Any condition associated with a life expectancy of less than 6 months.
* Participation in unrelated research involving investigational pharmacological agent(s) 30 days before planned dosing.
* Current alcohol or drug abuse.
* Inability to provide written informed consent.

+Locations (5)

FacilityCityCountryStatus
OLVZ AalstAalstBelgium
CHU ST-PierreBrusselsBelgium
HĂ´pital CardiologiqueLilleFrance
Catharina ZiekenhuisEindhovenNetherlands
King's College University HospitalLondonUnited Kingdom

+Investigators

My Notes